National Institutes of Health to Grant Exclusive Evaluation Option License to Angio360 Diagnostics for Cancer Diagnostic Tests

Summary

The National Institutes of Health is considering granting a Start-Up Exclusive Evaluation Option License Agreement to Angio360 Diagnostics, a Wisconsin-based company, to develop diagnostic tests and kits for detecting pathological angiogenesis in cancer, as outlined in several provisional and patent applications filed between 2006 and 2009.